Congress sets its sights on bringing down IPAB

Share this article:
Sen. John Cornyn (R-TX)
Sen. John Cornyn (R-TX)

Congressional Republicans—and a few Democrats—are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.

In February, the House Energy and Commerce Health Subcommittee voted 17-5 to repeal IPAB, the primary cost-cutting mechanism of the Affordable Care Act. The panel's 15 Republicans were joined by two Democrats representing pharmacentric districts. A similar bill, authored by Sen. John Cornyn (R-TX), is bottled up in the Senate.

In a post to The Hill's Congress Blog, the author of the House bill, Tennessee Republican Phil Roe, called IPAB a “dangerous rationing board.”

Starting in 2015, IPAB will be able to issue binding recommendations for cutting Medicare spending that will take effect unless Congress makes alternate cuts.

PhRMA and the AMA oppose the board. PhRMA SVP Matt Bennett says it “could enact sweeping Medicare changes without Congress' oversight… We believe IPAB will result in access problems for Medicare beneficiaries.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?